


A data-driven decision making framework for the selection, application, and development of advanced in-vitro models for preclinical drug development.

Our Data is our greatest asset and opport unity

Daniela Ortíz Franyuti, Desirée Schubert, Lauriane Cabon, Ekaterina Breous-Nystrom

Roche Pharma Research and Early Development Investigative and Immuno Safety Pharmaceutical Sciences Roche Innovation Center Basel








Translation Rate from pre-clinical models to Clinical Trials We need to **make better predictions**



up research. Nature 563, 317-319 (2018).

HIGH FAILURE RATE

In 7,455 drug-development programmes from 2006 to 2015, fewer than 10% of experimental drugs were found to be safe and effective, and then approved for market.



What makes it challenging to make good predictions?

Humans are not animals - Diverse palette of advanced in-vitro models rapidly evolving and expanding





Evart, L & Roth, A. Nat Rev Drug Dscov 20, 327-328 (2021).

Opportunities and challenges with microphysiological systems: a pharma end-user perspective

Lorna Ewart' and Adrian Roth2

Using human-relevant, translational in vitro models is widely considered to reduce attrition during drug discovery and development. Despite this, the adoption of models based on microphysiological systems — organs-on-chips or organoids — by pharma companies is moderate at best, and realizing the full potential of these models will need greater collaboration between stakeholders.

Available online at www.sciencedirect.com

ScienceDirect



Breous-Nystrom, E et al. Curr Opin Toxicol 23-24, 39-45 (2020).

Transforming preclinical assessment to meet clinical relevance with advanced models


Ekaterina Breous-Nystrom, Sven Kronenberg, Estelle Marrer-Berger, Adrian Roth, Thierry Lave and Thomas Singer






What makes it challenging to make good predictions?

Biological Diversity - Why do we respond different to a treatment? - Patient Stratification



Growing arsenal of therapeutic modalities - Complex mode of action



Iabrijn, A.F., Janmat, M.L., Reichert, J. M&Parren, P. W.H.I. Bispecific antibodies: a mechanistic review of the pipeline. *Nature reviews Drug discovery* 18, 585–608 (2019).

Honkala, A, et.al. Harnessing the predictive power of preclinical models for oncology drug development. *Nat Rev Drug Discov* 21, 99–114 (2022).



What makes it challenging to make good predictions?

Reproducibility is a real challenge - Especially for long term learning cycles

BIOMEDICINE

Key cancer results failed to be reproduced

Project to replicate high-impact preclinical cancer studies delivers sobering verdict

SCIENCE FORUM

An open investigation of the reproducibility of cancer biology research

Abstract It is widely believed that research that builds open previously published lindings has reproduced the original work. However, it is rare for researchers to perform or publish direct

TIMOTHY M ERRINGTON*, ELIZABETH IORNS, WILLIAM GUNN, FRASER ELISABETH TAN, JOELLE LOMAX AND BRIAN A NOSEK*

Errington, T. M. et al. Elife 3, e04333 (2014).



Barriers to reproducing preclinical results included unhelpful author communication.

Mullard, A Half of top cancer studies fail highprofile reproducibility effort. Nature 600, 368–369 (2021).

Kaiser J. Science. 2021 Dec 10;374(6573):1311.

PROJECT CANCER BIOLOGY

Investigating the replicability of preclinical cancer biology


Timothy M Errington's, Maya Mathur³, Courtney K Soderberg¹, Alexandria Denis¹⁷, Nicole Perfito¹⁴, Elizabeth Iorns³, Brian A Nosek¹⁴

'Center for Open Science, Diarlottenville, United States, 'Duanitative Sciences Unit, Stanford University, Stanford, United States, 'Science Exchange, Palo Alto, United States, 'University of Virginia, Charlotterville, United States

Errington, T. M et al. Eife 10, e71601 (2021).

Disappointing numbers

Out of 53 prominent preclinical cancer papers, only 23 could be put to the test, and many did not have clearly reproducible results.



Key Learnings


Reporting Standards Documentation:

Experiment, Materials, Data, Code, Analysis

- Registration
- Transparency Incentives for
- Replication




Learnings on translational power arrive YEARS after clinical trial start AND we still need to make decisions TODAY before clinical trials get started...



How do we put a molecule in the clinic? Without animal studies Enabling Entry into Human (EiH) In-vitro ONLY Safety Regulatory Package

TCR-like TCB that binds to a peptide (vs a protein) in the context of the MHC complex- Animal safety testing not possible due to the human-animal MHC mismatches and peptidome differences



Many Sources

Internal, Collaborators

Roche

External (CRO)

Variable Complexity

2D, Organoids, Spheroids Mcrophysiological Systems

Variable Readouts

Cytokines, PCR, Functional Low Dimensional, Mcroscopy, How Cytometry, CMCS




9

Data integration and interpretation at different levels

For each model, replicate, timepoint, readout...

Electrophysiology

Microscopy





Today's Challenges - Data driven decision-making How do we deal with ~3+ Million Conditions?!

Challenges:

- Multi-Model
- Multi-Readout
- Complex integration
- Complex interpretation
- Difficult to proof translatability
- Portfolio with large, complex, evolving molecules
- Physiological Relevance
- Technical complexity
- Evolving models

In Numbers:

- 21 Organ Tissues Tested
- **4** Levels of complexity
- 5+ different sites/labs (including CROs and collaborators)
- 4+ Biological Replicates
- 3+ Technical Replicates on biological samples
- **3**+ Technical Replicates on readouts
- 4+ Treatments
- **2** (+/-) Inflammation conditions
- 4+ Doses
- 4+ Time-points
- ~30+ Different <u>Readout Types</u>

= 2,903,040+ Conditions

(and more...)

Plus Metadata on:

- Individual
- Tissue
- Biospecimen (Cells/ organoids)
- Experiment
- Platform
- Samples
- Readouts
- Analysis



Think about trying to find and understand these data in 10 years time ... could you do it?





We can only do it with good scientific data management Prospective FAIR Data is a framework to get there

www.nature.com/scientificdata

SCIENTIFIC DATA

SUBJECT CATEGORIES + Research data · Publication characteristics

OPEN Comment: The FAIR Guiding Principles for scientific data management and stewardship Mark D. Wilkinson et al." Wilkinson, M.D. et al., Sci Data 3, 160018 (2016).



Findability Where are our data?



Accessibility How can I get the data?



FAIR

DATA

Interoperability How can I connect or integrate the data?



DECISIONS

INSIGHTS


KNOWLEDGE

PROCESSED DATA

RAW DATA

Analyucs

Reusability Can our data be easily shared and used again?



Oald Admingtonient




End-to-End FAIR Data Management

Human Biology-centric. Privacy/Confidentiality Compliance Planning, Sourcing, Implementing, Generating Data...

Different Labs. Low dim Low Dim Readouts CRO, Collaborators DatasetiD Data Entry Sample (D. 200 Point Data Data Entry Processed Data Sample ID 400 Point Study_ID Data Entry Data Entry Point Human relevant Point OMICS, etc. in-vitro Models Hi-dim nple_ID_10 Study ID Readouts Sample_ID_20 Study_ID Sample_ID. 500 Sample_ID_1 Study ID Sample ID 600 DatasetID Sample JD 21 Microscopy Study_ID Individual_ID Microscop Study ID Sample_ID 30 Sample ID 2 Study_ID DatasetID Sample ID 600 **Data Integration and** ample ID 31 FC/FACS Modelling Sample, ID 3 Study_ID Sample_ID_40 Flow Cytometry Metadata Sample ID, 500 Database Study ID DatasetID Sample_ID_600

Specimen Lineage, Metadata collection and storage

- **Decision Making-GO/NO-GO?**
- **De-risking Strategy**
- **Regulatory Filing**
- **Connectivity to Clinical Data** Repositories
- **Increase Confidence on** Translation Power






Reverse and Forward Translation rely on long term data

Make our data FAIR and SHARED to accelerate generating meaningful insights

Enhanced Data & Insights Sharing (EDIS) Program





Planning



Planning for how we bring data into Roche avoids wasted time later trying to fix inconsistencies. reconcile samples, and link content back together.

Acquisition

Taking steps to ensure FAIR data at acouisition avoids wasted time later trying to find or FAIRify data and documents.

Processing

Data processing enhances early FAIRification activities by improving the context, quality, and value prior to release and use.

Release

Processed data must be released to a system that can support versioning, metadata annotation, intuitive search engines, and accessibility for reuse.


Reuse




Reusable data are available for answering new scientific questions and supporting new analyses internally and, in some cases, externally,

Extend FAIR Clinical Data Practices to in-vitro work

Move toward Prospective FAIRification Internally and with our Partners. Collaborators and Vendors





We get there by standing on the shoulders... of a GIANT community of incredible colleagues

Lauriane Cabon **Desiree Schubert Ekaterina Breous-Nystrom** Cvrill Roth Margery Rousseille Linda Steinacher Virginie Micallef Laurent Juglair Giacomo Lazzaroni Nick Corr Susanne Fischer **Regine Gerard Blandine** Avignon Nikolche Giorevski Salma Sadok Nathalie Schaub **Evelyne Durr** Ramona Nudischer Estelle Marrer-Berger Adrian B. Roth Tim Hickling Marianne Manchester

Shanon Seger Cora Wiesner Diren Tas Moritz Gilsdorf Wojciech Kwiatkowski Michel Petrovic Angelo D'Annunzio Vanessa Schumacher

Laura Badi Guido Steiner Cyrill Lopez David Zhang Fabian Birzele

Tom Quaiser Silvia Jimenez Joachim Rupp

Collaborators and Contractors: Alveolix Mimetas In-Sphero CN-Bio Emulate Lonza StemCell Crown Biosciences SUN Biosciences pRED Roche Innovation Center Basel Pharmaceutical Sciences OneD In-Vitro FAIR Data Workgroup Roche Terminology Service PS FAIR Data Network pRED Informatics

125 YEARS

Celebrate Life

THANK YOU!